StemCells Inc  

(Public, NASDAQ:STEM)   Watch this stock  
Find more results for StemCells Inc
0.534
-0.015 (-2.66%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.53 - 0.55
52 week 0.49 - 2.43
Open 0.55
Vol / Avg. 811,882.00/2.97M
Mkt cap 56.12M
P/E     -
Div/yield     -
EPS -0.52
Shares 105.10M
Beta 1.71
Inst. own 10%
Aug 10, 2015
Q2 2015 StemCells Inc Earnings Release (Estimated) Add to calendar
Jul 8, 2015
StemCells Inc at Cantor Fitzgerald Inaugural Healthcare Conference - 11:45AM EDT - Add to calendar
May 28, 2015
StemCells Inc at Marcum MicroCap Conference
May 5, 2015
Q1 2015 StemCells Inc Earnings Call - Webcast
May 5, 2015
Q1 2015 StemCells Inc Earnings Release
Apr 27, 2015
GTC Stem Cell Summit 2015
Apr 15, 2015
StemCells Inc at Needham Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -44527.14% -3186.58%
Operating margin -42668.52% -3294.23%
EBITD margin - -2924.08%
Return on average assets -139.75% -87.21%
Return on average equity -2128.21% -309.83%
Employees 69 -
CDP Score - -

Address

3155 PORTER DRIVE
PALO ALTO, CA 94304
United States - Map
+1-650-4753100 (Phone)
+1-510-4564001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. The Company's lead product development program is its CNS Program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology. It is in clinical development with its HuCNS-SC cells for a range of diseases and disorders of the central nervous system. The CNS consists of the brain, spinal cord and eye, and it is stem cell company in clinical development for indications in all three compartments comprising the CNS, which include with respect to the brain, with respect to the spinal cord and with respect to the eye. The Phase I clinical trial was completed in Pelizeaus-Merzbacher Disease, Neuronal Ceroid Lipofuscinosis and Phase I/II clinical trial in multiple sites for chronic spinal cord injury was completed.

Officers and directors

John J. Schwartz Ph.D. Independent Chairman of the Board
Age: 80
Bio & Compensation  - Reuters
Ian J. Massey Ph.D. President, Chief Operating Officer
Age: 65
Bio & Compensation  - Reuters
Martin M. McGlynn Chief Executive Officer, Director
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gregory T. Schiffman Chief Financial Officer, Executive Vice President - Finance
Age: 57
Bio & Compensation  - Reuters
Ann Tsukamoto Ph.D. Executive Vice President - Scientific and Strategic Alliances
Age: 62
Bio & Compensation  - Reuters
Kenneth Blair Stratton J.D. General Counsel
Age: 46
Bio & Compensation  - Reuters
Alan O. Trounson Ph.D. Director
Age: 69
Bio & Compensation  - Reuters
Irving L. Weissman M.D. Director
Age: 75
Bio & Compensation  - Reuters
Eric H. Bjerkholt Independent Director
Age: 55
Bio & Compensation  - Reuters
R. Scott Greer Independent Director
Age: 56
Bio & Compensation  - Reuters